Biolife Solutions (BLFS) EBIAT (2016 - 2025)
Biolife Solutions (BLFS) has disclosed EBIAT for 16 consecutive years, with $11.1 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 53.6% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.6 million, a 131.09% decrease, with the full-year FY2025 number at -$4.6 million, up 47.69% from a year prior.
- EBIAT was $11.1 million for Q4 2025 at Biolife Solutions, up from $603000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $91.0 million in Q4 2022 to a low of -$72.9 million in Q2 2022.
- A 5-year average of -$2.7 million and a median of -$4.4 million in 2024 define the central range for EBIAT.
- Biggest YoY gain for EBIAT was 677.99% in 2022; the steepest drop was 14018.99% in 2022.
- Biolife Solutions' EBIAT stood at -$15.7 million in 2021, then skyrocketed by 677.99% to $91.0 million in 2022, then crashed by 116.44% to -$15.0 million in 2023, then surged by 259.51% to $23.9 million in 2024, then crashed by 53.6% to $11.1 million in 2025.
- Per Business Quant, the three most recent readings for BLFS's EBIAT are $11.1 million (Q4 2025), $603000.0 (Q3 2025), and -$15.8 million (Q2 2025).